Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women

PHASE4RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions
EstrogenPremenopause
Interventions
DRUG

ganirelix acetate

Ganirelix acetate (Antagon) will be used to prevent endogenous production of ovarian hormones in young women. Ganirelix is derived from native GnRH, and acts by competitively blocking GnRH receptors on the pituitary and subsequent pathways. Thus, administration of the GnRH antagonist (GnRHant) suppresses steroidogenesis, leading to low or undetectable serum estrogen and progesterone concentrations, which occurs within two days of initiation of administration. Women will self-administer subcutaneous injections (0.25 mg/day in 0.5 ml of normal saline) of the GnRH antagonist ganirelix acetate (Antagon, Organon, Inc., West Orange, New Jersey,) every day for \~12-15 days (starting on day \~2-4 of the menstrual cycle). Testing will occur on day 3-4 and day14-15 of using Antagon.

Trial Locations (1)

19713

RECRUITING

University of Delaware, Newark

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

University of Delaware

OTHER